The FDA has just expanded the use of Afatinib as a first line treatment to include a rare subset of people with metastatic non-small cell lung cancer (NSCLC)
This blog is focused on providing people who have been diagnosed with either a rare cancer or with more than one cancer a place where they can keep up with information, research and discoveries that could impact their lives in the near term.
Rare cancers and multiple cancers have been ignored for too long. Research dollars are far too limited.
Please let us know if you hear of anything new that needs to be shared with our community.
